Great grand multiparity: is it a risk?

A T Abu-Heija1, H E Chalabi

  • 1Department of Obstetrics and Gynaecology, Jordan University of Science and Technology.

We wished to compare antenatal and intrapartum complications among women delivering for the 10th or subsequent time and to compare them with women of lower parity (para 2-5). The records of 154 women of great grand parity (para >/= 10) were reviewed and compared with 308 women (para 2-5) delivered during the same period. Antepartum as well as intrapartum complications were compared. All the women delivered between 16 April 1994 and 15 January 1995. Great grand multiparous women were, not surprisingly, older. The incidence of diabetes millitus, chronic hypertension, preterm labour are similar to those with low parity while they have higher incidence of pre-eclampsia (7.1% vs. 2.6%) and intrauterine fetal death (5.2 vs. 1.3%) P < 0.04. There were no differences in the incidence of placental abruption, placenta previa, malpresentation and postpartum haemorrhage between the two groups. Great grand multipara had a higher incidence of macrosomia (7% vs. 2%) and operative delivery (20.6% vs. 11.4%) P < 0.02. Great grand multiparous woman are at some increased risk of having severe pre-eclampsia, intrauterine fetal death macrosomia and subsequently operative delivery with its associated risk of maternal mortality and morbidity.

Related Concept Videos

Probability Laws01:49

Probability Laws

Overview
Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...